SOFIE
GenericsSOFIE is a generic drug manufacturer focused on Oncology, Neurology, Gastroenterology.
SOFIE's Key Drugs
SOFIE's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
SOFIE's Recent FDA Approvals
New NDA/BLA approvals for SOFIE over the last two years — novel drugs only, excluding generics and label supplements.
SOFIE's Therapeutic Areas
SOFIE's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SOFIE's Top Competitors
SOFIE's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and EMD SERONO. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SOFIE Pipeline Snapshot
SOFIE has 6 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 3 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
2 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2012-12-14
- Latest
- 2023-05-12
- Applications
- 8